Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Nephrology

Life with Lupus Nephritis: Protecting Your Kidneys Long-Term

At a Glance

Long-term lupus nephritis care focuses on preventing kidney damage through regular urine and blood tests, blood pressure control, appropriate maintenance medicines, healthy habits, and planned pregnancy care with a rheumatology and nephrology team.

Successfully managing lupus nephritis (LN) over the long term is a marathon, not a sprint. While your initial treatment focuses on stopping active inflammation, the goal of daily management is to prevent future flares and protect your kidneys from the slow development of Chronic Kidney Disease (CKD). By staying ahead of the disease with regular monitoring and protective therapies, you and your care team can preserve your kidney function for years to come.

The Shield: Protecting Your Kidney Filters

Once your immune system is stabilized, your doctors will focus on “non-immune” ways to protect your kidneys. These treatments reduce the physical stress on your kidney’s filters:

  • RAAS Blockade: Medications known as ACE inhibitors (like lisinopril) or ARBs (like losartan) may be recommended when appropriate. They lower the pressure inside your kidney’s filters and reduce proteinuria (protein in the urine) [1][2]. Using these blockers is associated with a lower risk of kidney disease progression over time [2]. They require potassium and creatinine monitoring, and should not be combined routinely. Crucially, ACE inhibitors and ARBs are contraindicated in pregnancy.
  • Blood Pressure Control: High blood pressure is both a cause and a result of kidney damage. While goals are individualized, many protocols aim for a blood pressure below 130/80 mmHg [3][4]. Persistent high blood pressure is one of the strongest predictors of long-term kidney damage in lupus [5][4].
  • SGLT2 Inhibitors: Originally for diabetes, drugs like dapagliflozin are emerging as an individualized “add-on” choice for LN patients who still have some protein in their urine despite other treatments [6][7]. They are not a substitute for immune treatment, and their use depends on your specific kidney function, infection risks, and clinician review after your lupus is no longer “active” and your kidney function has stabilized [6][8].

The Blueprint for Monitoring

You will likely need blood and urine tests every 3 to 6 months during maintenance, and more frequently during active disease or medication changes [9]. Your team is looking for several key markers:

  1. Proteinuria (UPCR): This measures how much protein you are losing. A “Complete Renal Response” generally means your protein level has dropped below 0.5 to 0.7 g/g (or g/day on a 24-hour collection) and your kidney function (eGFR) is stable [5][10].
  2. eGFR/Creatinine: These blood tests measure how well your kidneys are filtering waste [11].
  3. Lupus Activity Markers: Tests for anti-dsDNA antibodies and complement levels (C3 and C4) help assess risk [11][12]. While trends in these markers can support risk assessment, they do not perfectly predict every flare and cannot replace direct urine and kidney-function monitoring.

Planning for the Future: Pregnancy and Fertility

If you hope to become pregnant, the most important rule is planning. Pregnancy is safest when your lupus and kidney disease have been in “quiet” remission for at least 6 months [13][14]. You should never stop or switch medications on your own.

  • Pregnancy-Compatible Options: Azathioprine, hydroxychloroquine, and tacrolimus are generally considered compatible with pregnancy [15][16][17]. Coordinated care with maternal-fetal medicine is essential.
  • Medications to Avoid: Mycophenolate Mofetil (MMF) and cyclophosphamide must be stopped and replaced with a safe alternative under specialist supervision before conception because they can cause severe birth defects or pregnancy loss [16][18]. ACE inhibitors, ARBs, and SGLT2 inhibitors must also be stopped for pregnancy.
  • Fertility Preservation: Because some treatments (especially cyclophosphamide) can affect future fertility, men and women should discuss options like sperm or egg banking before starting intensive therapy [19][20].

Daily Habits for Kidney Health

Small daily choices can have a large impact on your long-term outcomes:

  • Infection Prevention: Immunosuppressants increase infection risk. Stay up to date on vaccines (like flu and pneumococcal) and discuss sick-day precautions with your doctor.
  • Low-Sodium Diet: Reducing salt helps control your blood pressure and allows your ACE inhibitors or ARBs to work more effectively [4].
  • Healthy Weight: Managing obesity reduces the workload on your kidneys and helps prevent other complications [4].
  • Avoid “Nephrotoxins”: Be cautious with medications like NSAIDs (ibuprofen, naproxen), which can be hard on the kidneys. Always check with your nephrologist before starting any new over-the-counter supplement or medication [4].

If your labs remain stable and you reach your protein targets by the 12-month mark, you are on the best path toward long-term kidney health [21][22]. If your numbers are not improving as expected, your doctor may suggest a repeat biopsy to see if the “activity” (inflammation) has turned into “chronicity” (scarring) [11]. Regardless of the results, your active participation in monitoring is your strongest tool.

Common questions in this guide

How often should I have kidney tests with lupus nephritis?
During maintenance treatment, blood and urine tests are often done every 3 to 6 months. Testing may be more frequent during an active flare or after medication changes and usually includes urine protein, creatinine, kidney filtration estimates, anti-dsDNA, and complement levels. Your care team will set the schedule for you.
What blood pressure goal is usually recommended for lupus nephritis?
Your goal should be individualized, but many protocols aim for below 130/80 mmHg. Keeping blood pressure controlled is important because persistent high readings can accelerate kidney damage. Ask your care team how often to check it at home and which readings should prompt a call.
What does a complete renal response mean in lupus nephritis?
It generally means protein in the urine has fallen to below about 0.5 to 0.7 grams per gram, or grams per day on a 24-hour collection, while kidney filtration remains stable. Your clinician interprets this target together with your kidney function and overall lupus activity.
Could an SGLT2 inhibitor help protect my kidneys?
An SGLT2 inhibitor may be considered as an add-on when some protein remains in the urine despite other treatment. It is not a replacement for immune treatment, and suitability depends on kidney function, infection risk, and whether lupus activity has settled. Your clinician should decide if it is appropriate.
How should I prepare for pregnancy with lupus nephritis?
Pregnancy is generally safest after lupus and kidney disease have been quiet for at least six months. Before conception, coordinate with your rheumatologist, nephrologist, and maternal-fetal medicine team to review medicines; do not stop or switch them yourself. Mycophenolate, cyclophosphamide, ACE inhibitors, ARBs, and SGLT2 inhibitors need to be stopped or changed under specialist supervision, while azathioprine, hydroxychloroquine, and tacrolimus are generally considered pregnancy-compatible.
When might a repeat kidney biopsy be considered?
If protein levels or kidney function are not improving as expected at around 6 or 12 months, your doctor may consider a repeat biopsy. It can help show whether ongoing inflammation is still active or whether scarring has become the main problem. A biopsy is not automatically needed for everyone.
What daily habits can help protect my kidneys with lupus nephritis?
Limiting salt, maintaining a healthy weight, staying current on recommended vaccines, and checking before using ibuprofen, naproxen, supplements, or other new medicines can support kidney health. NSAIDs can be hard on the kidneys, so ask your nephrologist about over-the-counter pain relievers. These steps complement, but do not replace, your prescribed lupus treatment.

Get notified when new evidence is published on Lupus nephritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Control Study.

    Tselios K, Gladman DD, Su J, Urowitz MB

    Arthritis care & research 2016; (68(10)):1497-504 doi:10.1002/acr.22857.

    PMID: 26866934
  2. 2

    Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable?

    Tselios K, Gladman DD, Su J, Urowitz MB

    The Journal of rheumatology 2020; (47(9)):1366-1373 doi:10.3899/jrheum.191064.

    PMID: 32238519
  3. 3

    Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression.

    Castro M, Ugolini-Lopes M, Borba EF, et al.

    Lupus 2018; (27(14)):2215-2219 doi:10.1177/0961203318809883.

    PMID: 30394834
  4. 4

    Lupus nephritis-related chronic kidney disease.

    Lichtnekert J, Anders HJ

    Nature reviews. Rheumatology 2024; (20(11)):699-711 doi:10.1038/s41584-024-01158-w.

    PMID: 39317803
  5. 5

    Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis.

    Moroni G, Gatto M, Tamborini F, et al.

    Annals of the rheumatic diseases 2020; (79(8)):1077-1083 doi:10.1136/annrheumdis-2020-216965.

    PMID: 32503858
  6. 6

    Sodium-glucose cotransporter 2 inhibitors: are they ready for prime time in the management of lupus nephritis?

    Wagner BR, Rao PS

    Current opinion in rheumatology 2024; (36(3)):163-168 doi:10.1097/BOR.0000000000001002.

    PMID: 38517337
  7. 7

    Efficacy and safety of dapagliflozin in inactive lupus nephritis: a randomized crossover trial.

    Vajgel G, Júnior BMDS, Filho CRSM, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2026; (41(7)):1253-1261 doi:10.1093/ndt/gfaf257.

    PMID: 41324239
  8. 8

    Sodium-glucose cotransporter 2 (SGLT2) inhibition and autoimmunity.

    Kronbichler A

    Seminars in arthritis and rheumatism 2025; (72S()):152663 doi:10.1016/j.semarthrit.2025.152663.

    PMID: 40016066
  9. 9

    2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.

    Fanouriakis A, Kostopoulou M, Cheema K, et al.

    Annals of the rheumatic diseases 2020; (79(6)):713-723 doi:10.1136/annrheumdis-2020-216924.

    PMID: 32220834
  10. 10

    Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.

    Furie R, Rovin BH, Houssiau F, et al.

    The New England journal of medicine 2020; (383(12)):1117-1128 doi:10.1056/NEJMoa2001180.

    PMID: 32937045
  11. 11

    II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment.

    Reis-Neto ETD, Seguro LPC, Sato EI, et al.

    Advances in rheumatology (London, England) 2024; (64(1)):48 doi:10.1186/s42358-024-00386-8.

    PMID: 38890752
  12. 12

    Biomarkers in Lupus Nephritis: An Evidence-Based Comprehensive Review.

    Vrabie A, Obrișcă B, Sorohan BM, Ismail G

    Life (Basel, Switzerland) 2025; (15(10)) doi:10.3390/life15101497.

    PMID: 41157170
  13. 13

    Balancing stringency and feasibility: comparative value of disease-activity measures to predict pregnancy outcomes in systemic lupus erythematosus.

    Chen Y, Lin S, Wang M, et al.

    Lupus science & medicine 2026; (13(1)) doi:10.1136/lupus-2025-001793.

    PMID: 41571408
  14. 14

    Pregnancy outcome in women with active and inactive lupus nephritis: A prospective cohort study.

    Attia DH, Mokbel A, Haggag HM, Naeem N

    Lupus 2019; (28(7)):806-817 doi:10.1177/0961203319846650.

    PMID: 31084235
  15. 15

    Pro: Cyclophosphamide in lupus nephritis.

    Kallenberg CG

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2016; (31(7)):1047-52 doi:10.1093/ndt/gfw069.

    PMID: 27190359
  16. 16

    Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy.

    , Silver R, Craigo S, et al.

    American journal of obstetrics and gynecology 2023; (228(3)):B41-B60 doi:10.1016/j.ajog.2022.09.001.

    PMID: 36084704
  17. 17

    Tacrolimus use and renal function in pregnancy with lupus nephritis: Analysis of post-marketing surveillance data in Japan.

    Suzuki K, Uno S, Wakasugi N

    Modern rheumatology 2023; (33(5)):944-952 doi:10.1093/mr/roac094.

    PMID: 35982545
  18. 18

    Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy.

    Golubović S, Živković S, Veselinov V, et al.

    Lupus 2026; (35(12)):1217-1226 doi:10.1177/09612033261469025.

    PMID: 42420832
  19. 19

    Con: Cyclophosphamide for the treatment of lupus nephritis.

    Mok CC

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2016; (31(7)):1053-7 doi:10.1093/ndt/gfw068.

    PMID: 27190358
  20. 20

    Male infertility in lupus nephritis: Clinical implications and management strategies.

    Elahi T, Ahmed S, Mubarak M

    Lupus 2026; (35(10)):1003-1012 doi:10.1177/09612033261454513.

    PMID: 42161342
  21. 21

    Clinical, Histologic, and Serological Predictors of Renal Function Loss in Lupus Nephritis.

    Zhang S, Magder L, Goldman D, et al.

    Arthritis care & research 2026; doi:10.1002/acr.80070.

    PMID: 42047336
  22. 22

    Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis.

    Mok CC, Ho LY, Ying SKY, et al.

    Annals of the rheumatic diseases 2020; (79(8)):1070-1076 doi:10.1136/annrheumdis-2020-217178.

    PMID: 32448782

This page is for informational purposes only and does not constitute medical advice. Your rheumatologist and nephrologist should guide medication changes, pregnancy planning, and kidney monitoring.

Guide contents Lupus nephritis
Research & Literature
04 Standard Treatments